Quantitative [ 68 Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study.
Jake KendrickRoslyn Jane FrancisGhulam Mubashar HassanPejman RowshanfarzadJeremy S L OngNathaniel BarryBranimir RusanovMartin Andrew EbertPublished in: Scientific reports (2023)
[ 68 Ga]Ga-PSMA-11 PET has become the standard imaging modality for biochemically recurrent (BCR) prostate cancer (PCa). However, its prognostic value in assessing response at this stage remains uncertain. The study aimed to assess the prognostic significance of radiographic patient-level patterns of progression derived from lesion-level biomarker quantitation in metastatic disease sites. A total of 138 BCR PCa patients with both baseline and follow-up [ 68 Ga]Ga-PSMA-11 PET scans were included in this analysis. Tumour response was quantified at the lesion level using commonly used quantitative parameters (SUV mean , SUV max , SUV peak , volume), and patients were classified as systemic, mixed, or no-progression based on these response classifications. A total of 328 matched lesions between baseline and follow-up scans were analysed. The results showed that systemic progressors had a significantly higher risk of death than patients with no progression with SUV mean demonstrating the highest prognostic value (HR = 5.70, 95% CI = 2.63-12.37, p < 0.001, C-Index = 0.69). Moreover, progressive disease as measured by SUV mean using the radiographic PSMA PET Progression Criteria (rPPP) was found to be significantly prognostic for patient overall survival (HR = 3.67, 95% CI = 1.82-7.39, p < 0.001, C-Index = 0.65). This work provides important evidence supporting the prognostic utility of PSMA response quantitation in the BCR setting.
Keyphrases
- pet ct
- prostate cancer
- positron emission tomography
- acute lymphoblastic leukemia
- high resolution
- end stage renal disease
- mass spectrometry
- computed tomography
- case report
- radical prostatectomy
- ms ms
- squamous cell carcinoma
- ejection fraction
- small cell lung cancer
- chronic kidney disease
- multiple sclerosis
- high performance liquid chromatography
- newly diagnosed
- peritoneal dialysis
- liquid chromatography tandem mass spectrometry
- magnetic resonance imaging
- liquid chromatography
- patient reported outcomes
- photodynamic therapy
- tandem mass spectrometry
- patient reported